Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody–associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS
Clinical Rheumatology · 2024
DOI: 10.1007/s10067-024-07096-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Rheumatology, 2024. Verfasst von Genki Kidoguchi und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan. kidogen@hiroshima-u.ac.jp. Hauptthemen laut MEDLINE: Rituximab, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Recurrence, Remission Induction. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.
Abstract (Originalsprache)
We aimed to clarify the long-term safety and efficacy of rituximab (RTX) as a remission induction therapy following severe relapse in patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). We retrospectively collected the data of patients with severely relapsed AAV from a Japanese multicentre cohort. The primary exposure was RTX use; the primary outcome was complete remission (CR) proportions at week 24. Baseline characteristics were compared between the RTX and non-RTX groups. We performed multivariate logistic regression analysis and one-to-one propensity score matching analysis as a sensitivity analysis. Totally, 100 patients were enrolled: 52 in the RTX group and 48 in the non-RTX group. Baseline characteristics were comparable between the two groups, except for age, AAV subtype and ANCA serotype. The median age was 71 vs. 75 years, and the PR3-ANCA positivity rate was 44.2% vs. 18.8% in the RTX and non-RTX groups, respectively. No significant difference was observed in CR proportions at week 24 between the two groups (79.2% vs. 68.1%, p = 0.321), with an adjusted odds ratio of 1.27 (95% confidence interval [CI] 0.47–3.51). At week 48, CR proportions were significantly higher in the RTX group (91.7% vs. 64.9%, p = 0.005), with an adjusted odds ratio of 2.95 (95% CI 0.97–9.91). Serious infection rates were lower in the RTX group than in the non-RTX group, with no statistically significant difference. RTX was not superior to conventional immunosuppressive therapies at week 24 but showed significantly favourable results at week 48 for severely relapsed AAV. Key Points • RTX might be superior to traditional treatments as an induction therapy for severely relapsed AAV. • RTX has the potential to sustain long-term remission with fewer occurrences of infections in the treatment of severely relapsed AAV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan. kidogen@hiroshima-u.ac.jp.
- Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
- Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
- Department of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan.
- Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
Förderung
- Hiroshima University
Zitieren
APA
Kidoguchi, G., Yoshida, Y., Watanabe, H., Sugimoto, T., Mokuda, S., Kida, T., Yajima, N., Omura, S., Nakagomi, D., Abe, Y., Kadoya, M., Takizawa, N., Nomura, A., Kukida, Y., Kondo, N., Yamano, Y., Yanagida, T., Endo, K., Matsui, K., …, & Japan Collaborative Registry of ANCA-Associated Vasculitis (J-CANVAS) (2024). Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody–associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07096-y
Vancouver
Kidoguchi G, Yoshida Y, Watanabe H, Sugimoto T, Mokuda S, Kida T, et al. Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody–associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS. Clinical Rheumatology. 2024. doi:10.1007/s10067-024-07096-y
BibTeX
@article{Kidoguchi2024,
author = {Kidoguchi, Genki and Yoshida, Yusuke and Watanabe, Hirofumi and Sugimoto, Tomohiro and Mokuda, Sho and Kida, Takashi and Yajima, Nobuyuki and Omura, Satoshi and Nakagomi, Daiki and Abe, Yoshiyuki and Kadoya, Masatoshi and Takizawa, Naoho and Nomura, Atsushi and Kukida, Yuji and Kondo, Naoya and Yamano, Yasuhiko and Yanagida, Takuya and Endo, Koji and Matsui, Kiyoshi and Takeuchi, Tohru and Ichinose, Kunihiro and Kato, Masaru and Yanai, Ryo and Matsuo, Yusuke and Shimojima, Yasuhiro and Nishioka, Ryo and Okazaki, Ryota and Takata, Tomoaki and Ito, Takafumi and Moriyama, Mayuko and Takatani, Ayuko and Miyawaki, Yoshia and Ito-Ihara, Toshiko and Kawaguchi, Takashi and Kawahito, Yutaka and Hirata, Shintaro and Japan Collaborative Registry of ANCA-Associated Vasculitis (J-CANVAS), Japan Collaborative Registry of ANCA-Associated Vasculitis (J-CANVAS)},
title = {Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody–associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS},
journal = {Clinical Rheumatology},
year = {2024},
doi = {10.1007/s10067-024-07096-y}
}
EUVIMED